Abstract
Rationale Preserved ratio impaired spirometry (PRISm) is defined as Forced Expiratory Volume in one second <80% predicted with a FEV1/Forced Vital Capacity of >0.70. It may be a precursor of COPD and has been associated with increased respiratory symptoms and comorbidities. Current understanding of PRISm is based on small selective cohorts and genetic determinants remain unknown.
Objectives Identify the prevalence, risk factors, co-morbidity, and genetics of PRISm in a large cohort to improve power and generalizability.
Methods The UKBiobank, provides a large cohort of genotyped individuals. Regression analysis determined risk factors for and associated co-morbidities of PRISm. Genome wide association studies, conditional, and gene-based analyses were performed with a PheWAS and literature search conducted on the results.
Measurements and Main Results PRISm has a similar prevalence to airflow obstruction (8% vs 7.8%) and is associated with increased cardiovascular co-morbidity, OR of 1.26 (95%CI 1.20-1.31) after adjusting for BMI, smoking status, age, diabetes, and sex. Genetic analysis discovered four associated single nucleotide polymorphisms and eight genes. Two SNPs have not been described with respiratory disease before. Other genetic loci identified are known to increase risk of asthma and COPD, and influence response to inhaled steroids.
Conclusions PRISm affects 8% of adults of whom ∼40% report cardiovascular comorbidity. Detailed analysis reveals that PRISm has shared genetic associations with asthma and COPD. These findings highlight the need for research into the potential therapeutic strategies and screening for individuals with PRISm, in particular whether this may reduce transition to COPD and reduce cardiovascular disease.
Competing Interest Statement
Dr Dodd reports non-financial support from Chesi, personal fees from Chesi, Boerhinger Ingelheim, AstraZeneca, personal fees from GSK. All outside the submitted work
Funding Statement
Funding: This work was supported by the Medical Research Council and the University of Bristol Integrative Epidemiology Unit (MC_UU_00011). MRC CARP Fellowship (Grant ref: MR/T005114/1)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A Data already collected by UKBiobank. No ethical approval was required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by the Medical Research Council and the University of Bristol Integrative Epidemiology Unit (MC_UU_00011). MRC CARP Fellowship (Grant ref: MR/T005114/1)
Data Availability
Within 4 weeks of publication our GWAS results will be available online from https://gwas.mrcieu.ac.uk/
